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ABSTRACT
Introduction: Diagnosis of axial spondy
loarthritis (SpA) can be delayed for several years
mainly because of low awareness of axial SpA
among non-rheumatologists who are the first
interlocutors of potential SpA patients. One
strategy to decrease the delay between
appearance of first symptoms and diagnosis of
axial SpA and to allow early management of the
disease is to provide the non-rheumatologists
with tools to identify patients requiring prompt
referral to rheumatologists. This study was
designed to evaluate in a real-world setting
whether screening patients with chronic low
back pain who consult physical medicine and
rehabilitation (PMR) physicians, orthopedists,
and ophthalmologists is useful in detecting axial
SpA.
Methods: During this non-interventional
cross-sectional study, data from 161 patients
with chronic back pain, consulting an
orthopedist, PMR physician, or
ophthalmologist were collected during a single
visit. Any patient who presented with at least
four out of five symptoms of inflammatory back
pain (IBP) and at least one additional SpA
feature were to be referred to a rheumatologist.
Analysis was purely descriptive.
Results: IBP was diagnosed in approximately
half of the patients (89 patients) and 72 of them
met the referral criteria. A total of 117 patients
were finally referred to a rheumatologist and
axial SpA was diagnosed for 37 of them.
Conclusions: The high prevalence of
undiagnosed axial SpA in patients with
chronic back pain visiting PMR physicians,
orthopedists, and ophthalmologists suggests
that these healthcare professionals may play a
key role in the strategy developed to shorten the
delay observed in the formal diagnosis of SpA.
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INTRODUCTION
Lowback painhas been reported to affect 60–70%
of adults during their lifetime and is a regular
cause for seeking medical care [1, 2]. Low back
pain is defined as chronic if symptoms persist for
more than 3 months. Although chronic low back
pain is most often degenerative, in about 5% of
patients, the pain results from inflammation [3, 4]
and is referred to as inflammatory back pain (IBP).
One of the causes of IBP is axial spondyloarthritis
(SpA), of which the prevalence is approximately
0.5–1% in the general population [5–8]. Chronic
IBP has been identified as a major clinical feature
of SpA and is experienced by most patients,
whereas other peripheral or extra-articular
manifestations (inflammation of peripheral
joints with asymmetrical arthritis,
predominantly of the lower limb; occurrence of
enthesitis; uveitis) are present in approximately
40–60%ofpatients [6]. Axial SpA refers topatients
with predominant axial involvement and axial
complaints, and includes both ankylosing
spondylitis (AS), for which evidence of
sacroiliitis (another hallmark of SpA) is detected
onX-rays, andnon-radiographic axial SpA,where
sacroiliitis is visible via magnetic resonance
imaging (MRI) but not on X-rays [6]. Evidence
has been gathered that non-radiographic axial
SpAmight be anearly stage ofAS, althoughnot all
cases of axial SpA will progress to AS [9, 10]. A
strong association with Human Leucocyte
Antigen-B27 (HLA-B27) has also been evidenced
[11] and can be considered as the third main
clinical feature of axial SpA.
Based on these observations, over the past
seven decades, several criteria and algorithms
have been developed for the classification of AS
and axial SpA. In 2009, the Assessment of
SpondyloArthritis International Society (ASAS)
released a new set of criteria for SpA in patients
with chronic back pain [12–14]. The definition
of IBP has been revised [15]. Sacroiliitis on
imaging (X-rays or MRI) is the main criteria for
the imaging arm, whilst the presence of
HLA-B27 is the main criteria for the clinical
arm. The ASAS criteria are met if at least one (in
the imaging arm) or two (in the clinical arm)
other SpA features are present [IBP, arthritis,
enthesitis, uveitis, dactylitis, psoriasis, Crohn’s
disease/ulcerative colitis, good response to
nonsteroidal anti-inflammatory drugs
(NSAIDs), family history of SpA, HLA-B27 and
elevated C-reactive protein (CRP)] [12].
Although these criteria are intended for
classification, they could also be a useful
referral tool in the primary healthcare setting,
allowing non-rheumatologists to determine
whether referral to a rheumatologist is
necessary.
Axial SpA has an early onset (generally in the
second or third decade of life), whichmay hinder
early diagnosis, as younger individuals may be
less likely to promptly consult with a
rheumatologist. These individuals may first
turn to general practitioners or physical
medicine and rehabilitation (PMR) physicians
who are often the first interlocutors of potential
patients with SpA. Non-rheumatologist
specialists such as ophthalmologists and
orthopedists are also consulted when
extra-articular manifestations of the disease
occur (for instance, uveitis or dactylitis) [16]. It
is generally admitted that there is a delay of
5–10 years from the onset of symptoms
(generally stiffness and axial pain) to a final
diagnosis of AS [11, 14, 16]. On the other hand,
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efficient treatment strategies, such as NSAIDs,
and more recently tumor necrosis factor (TNF)
blockers, are available and seem to be most
effective in the early stages of the disease [15].
Signs and symptoms associated with axial SpA
(nocturnal pain, morning stiffness, fatigue,
limitation of spinal mobility and ultimately
ankylosis with disease progression) as well as
symptoms associated with peripheral
involvement, might seriously impact patient
quality of life and have a non-negligible cost for
society [17]. Facilitating an early diagnosis is
therefore among the objectives clearly identified
by ASAS to improve patient well-being [14, 18].
Some studies have highlighted the lack of
awareness among general practitioners,
especially regarding the disease spectrum and
early detection [3, 19]. One strategy to shorten
the delay between the occurrence of first
symptoms and the final diagnosis of AS is to
increase the awareness of SpA and AS among
primary healthcare professionals and
non-rheumatologist specialists, providing them
with tools to identify these patients among the
large population of patients with back pain.
Recently, several referral strategies, mostly
intended for general practitioners and primary
care professionals, have been developed to allow
earlier diagnosis [2, 10, 20, 21]. The SUSPECT
study was designed to evaluate whether real-life
screening of patientswith chronic back painwho
consult PMR physicians, orthopedists, and
ophthalmologists is useful indetecting axial SpA.
METHODS
Protocol Overview and Study Design
The SUSPECT study was approved by the ethics
committee of Erasme Hospital (Brussels,
Belgium) and conducted according to local
regulations. It has therefore been performed in
accordance with the ethical standard laid down
in the 1964 Declaration of Helsinki and its later
amendments. All patients gave written
informed consent prior to their enrollment in
the study.
SUSPECT was a non-interventional,
cross-sectional study that took place between
February 2011 and June 2013. No formal sample
size calculation was performed. The planned
number of patients (160) was defined on the
basis of the recruiting capacity of the
participating investigators. Data were collected
during one routine visit to a
non-rheumatologist investigator (orthopedists,
PMR physicians, and ophthalmologists)
practicing in university hospitals, regional
hospitals, or in private practice. Patients aged
18–45 years at inclusion, with chronic back pain
([3 months) and back pain at night were
eligible. Patients with diagnosed AS or SpA
were excluded. The patients were evaluated for
the presence of IBP based on the ASAS criteria
[12] and SpA features according to the ASAS
criteria for axial SpA [14]. Investigators were
requested to refer any patient who presented
with at least four of the five IBP symptoms and
at least one additional SpA feature to a
rheumatologist.
Demographic and baseline characteristics
(duration of pain, presence of IBP symptoms,
and SpA features) were collected during a single
routine visit on a first case report form (CRF).
For referred patients, investigators completed a
second CRF based on the information provided
by the rheumatologist (confirmation of
diagnosis, diagnosis parameter, treatment
initiated). Because this study was
observational, HLA-B27 determination was not
performed systematically (either by the
investigator or the rheumatologist); however,
the information was reported in the CRF when
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HLA-B27 results were available. The proportion
of patients with HLA-B27-positive results was
therefore not calculated. The number of
patients with a positive HLA-B27 result is
given for information purposes only; these
data should be considered with caution.
Outcome Measures
The proportion of patients with confirmed
diagnosis of axial SpA was evaluated and the
characteristics of the patients referred to a
rheumatologist were summarized.
Statistical Analysis
Descriptive analyses were performed using the
SAS package for Windows, version 9.2 (SAS,
Cary, NC, USA) on the full analysis set, which
consisted of all enrolled patients with available
information. Five subpopulations were defined:
patients referred to a rheumatologist, patients
agreeing to visit a rheumatologist, patients for
whom feedback from the rheumatologist was
available, patients with confirmed SpA
diagnosis and patients with confirmed
diagnosis not meeting the referral criteria (see
flow chart in Fig. 1 for more details).
RESULTS
Patient Demographics
A total of 27 investigators (three orthopedists,
six ophthalmologists, and 18 PMR physicians)
recruited 161 patients meeting the eligibility
criteria for the study (patients aged between 18
and 45 years old, with chronic back pain and
pain at night, having signed an informed
consent and without known axial SpA).
Patients ranged in age from 20 to 53 years,
with an average age of 36 years [standard
deviation (SD): 8 years]. Although the
inclusion criteria stated an age limit of
\45 years, 20 patients exceeded the age limit
(eight patients had an age equal to 45 years).
However, the decision was made to include
these 20 patients in the full analysis set. Indeed,
most of them (15/20) developed their back pain
before 40 years of age and the others (5/20) had
at least 2 SpA features. Of the 161 recruited
patients, 46% were male.
Baseline Characteristics and Referral
to a Rheumatologist
Of the 161 enrolled patients with back pain, 89
patients (55%) were diagnosed with IBP (at least
four of five symptoms of IBP). The most
frequently reported IBP symptoms ([85%)
were age at onset younger than 40 years and
pain at night (Table 1). The mean duration of
back pain at the time of inclusion was 4.2 years
(SD: 5.4 years; range, 2.5 months–25 years). A
total of 130 patients (81%) presented at least
one additional SpA feature. The most frequently
reported additional SpA feature (collected
before referral) was good response to NSAIDs
(42%). A total of 72 patients met the referral
criteria and 66 of them were referred to a
rheumatologist. Although they did not meet
referral criteria, 51 additional patients were
referred to a rheumatologist. From these 51
patients, 46 fitted less of five IBP criteria and five
had no SpA features according to the referring
physician. Then, a total of 117 patients were
advised to consult a rheumatologist, 104 agreed
to do so and feedback was collected on 85
patients (Fig. 1). A diagnosis of SpA was
confirmed for 37 patients (23.0% of the 161
enrolled patients, 31.6% of the referred
patients, and 43.5% of the 85 patients with a
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rheumatologist feedback), 15 of which had not
met the referral criteria.
Characteristics of Patients with Confirmed
Axial SpA Diagnosis
In general, rheumatologists felt confident with
their diagnosis (mean score[7 on a 0–10 scale).
The main characteristics of patients with
confirmed diagnosis of axial SpA are presented
in Table 2. The mean age (34, SD: 8 years), sex
ratio (41% male), and mean back pain duration
(4.2, SD: 5.4 years) of patients with confirmed
diagnosis of axial SpA are similar to those of the
total study population. All patients meeting
referral criteria had at least four IBP symptoms
as specified in the protocol. Some discrepancies
were observed between the SpA features
recorded by the investigator and those
recorded by the rheumatologist. For example,
sacroiliitis on imaging (X-ray, MRI, or CT scan)
was the most frequent SpA feature reported by
the rheumatologist (57%, Table 2), whereas
good response to NSAIDs for back pain was
the most frequent SpA feature reported by
investigators (42%, see previous paragraph).
Based on data from the rheumatologist
evaluation, 33 of the 37 patients with
Fig. 1 Patient dispo-
sition ﬂow chart
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confirmed diagnosis of SpA fulfilled the ASAS
classification criteria for axial SpA (89%). The
imaging arm criteria (sacroiliitis on imaging and
at least one SpA feature) were met by 22
patients, whereas the clinical arm criteria
(positive HLA-B27 result and at least two SpA
features) were met by 11 patients.
Overall, a new diagnosis of axial SpA was
confirmed by the rheumatologist for about
one-third of the referred patients.
DISCUSSION
In the SUSPECT study, 117 patients were
referred to a rheumatologist (73% of the 161
enrolled patients) and diagnosis was confirmed
for 37 patients, i.e., 23% of the enrolled patients
and 32% of the referred patients. This
proportion is similar to the prevalence
observed in the literature [2, 8, 20, 22–27]. The
primary healthcare professionals involved in
the SUSPECT study were not general
practitioners, but mainly PMR physicians and,
to a lesser extent, orthopedists and
ophthalmologists. Recently it was suggested
that increasing awareness of SpA in primary
healthcare professionals should not only focus
on general practitioners but also target
physicians who might encounter patients with
potential extra-articular manifestations such as
inflammatory bowel disease, psoriasis, or uveitis
in their daily practices [28]. Our study shows
that this is a valid point, underscoring the role
of PMR physicians, orthopedists, and
ophthalmologists in early diagnosis of SpA.
The fact that about 40% (15/37) of the
patients with confirmed diagnosis did not
meet the referral criteria proposed in the
SUSPECT protocol suggests that these criteria
(four of five IBP criteria and one additional SpA
Table 1 IBP symptoms
Patients All
enrolled
All
referred
With feed-back
from
rheumatologist
With
conﬁrmed
diagnosis
With conﬁrmed diagnosis but
not meeting referral criteria
N5 161 N5 117 N5 85 N5 37 N5 15
Number of IBP symptoms, n (%)
4 and 5 89 (55.3) 71 (60.7) 44 (51.8) 23 (62.1) 1 (6.7)
IBP symptoms, n (%)
Age at onset
\40 years
144 (89.4) 104 (88.9) 71 (83.5) 33 (89.2) 11 (73.3)
Insidious onset 106 (65.8) 78 (66.7) 52 (61.2) 23 (62.2) 5 (33.3)
Improvement with
exercise
92 (57.1) 71 (60.7) 48 (56.5) 24 (64.9) 5 (33.3)
No improvement
with rest
85 (52.8) 69 (59.0) 42 (49.4) 20 (54.1) 5 (33.3)
Pain at night
(improvement by
getting up)
141 (87.6) 101 (86.3) 72 (84.7) 34 (91.9) 12 (80.0)
IBP inﬂammatory back pain, n number of patients in the speciﬁed category
126 Rheumatol Ther (2017) 4:121–132
Table 2 Characteristics of patients with conﬁrmed axial SpA diagnosis
Patients With
conﬁrmed
diagnosis
With conﬁrmed diagnosis and
meeting referral criteria
With conﬁrmed diagnosis but
not meeting referral criteria
N5 37 N5 22 N5 15
Demography
Male, n (%) 15 (40.5) 8 (36.4) 7 (46.7)
Mean age (SD) 34.0 (7.7) years 34.4 (7.1) years 33.4 (8.7) years
Mean back pain duration (SD) 50.8 (65.3)
months
50.1 (64.7) months 52.0 (68.9) months
Number of IBP symptoms, n (%)
4 and 5 23 (62.1) 22 (100) 1 (6.7)
IBP symptoms, n (%)
Age at onset (\40 years) 33 (89.2) 22 (100) 11 (73.3)
Insidious onset 23 (62.2) 18 (81.2) 5 (33.3)
Improvement with exercise 24 (64.9) 19 (86.4) 5 (33.3)
No improvement with rest 20 (54.1) 15 (68.2) 5 (33.3)
Pain at night (with
improvement upon getting up)
34 (91.9) 22 (100) 12 (80.0)
Additional SpA features, n (%) as reported by the rheumatologist
Arthritis 4 (10.8) 1 (4.5) 3 (20.0)
Enthesitis of the heel 4 (10.8) 2 (9.1) 2 (13.3)
Uveitis conﬁrmed by
ophthalmologist
7 (18.9) 5 (22.7) 2 (13.3)
Dactylitis 1 (2.7) 1 (4.5) 0 (0.0)
Psoriasis 3 (8.1) 1 (4.5) 2 (13.3)
Inﬂammatory bowel disease
(Crohn, UC)
0 (0.0) 0 (0.0) 0 (0.0)
Family history of axial
spondyloarthritis, Crohn,
psoriasis
7 (18.9) 2 (9.1) 5 (33.3)
HLA-B27 positivea 22 13 9
Elevated CRP or ESR 5 (13.5) 3 (13.6) 2 (13.3)
Good response to NSAIDs for
back pain
6 (16.2) 4 (18.2) 2 (13.3)
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feature) may be too stringent. Several studies
have questioned the use of IBP as the main
clinical feature in the diagnosis of axial SpA
[11, 24] due to the specificity of IBP with regards
to its low prevalence among chronic back pain
patients [6]. Shortly after the end of the study
ASAS published recommendations for the early
referral of patients with suspicion of axial SpA
[29]: chronic back pain with onset before
45 years of age was retained as entry criterion;
and IBP, along with other axial SpA
characteristics (HLA-B27 positive, sacroiliitis
on imaging, peripheral and/or extra-articular
manifestation, positive family history for SpA,
good response to NSAIDs and elevated acute
phase reactants) was named as one of the
additional parameters, which should lead to
referral in those patients. This was defined in
line with the ASAS classification criteria in
which IBP was not proposed as a mandatory
entry criterion but as a SpA feature. IBP is, and
should remain, a key characteristic for screening
patients in primary care settings; however,
primary healthcare professionals should keep
in mind that absence of IBP should not exclude
a diagnosis of SpA [30]. This seems to be the case
in the current study, where two-thirds of the
patients with confirmed diagnosis that did not
meet the referral criteria (10/15) did not meet
the IBP criteria (presence of only three of the
IBP symptoms). Overall, all the referred patients
would have met the referral criteria as proposed
by the recently published ASAS
recommendation [29].
When the ASAS classification criteria for
axial SpA were applied, 89% of the patients
with confirmed diagnosis (33/37 patients) were
classified as having axial SpA: one-third via the
clinical arm of the ASAS criteria, which shows
the importance of this arm for early diagnosis of
axial SpA. These results are more or less in line
with the results observed in 2 cohort studies,
the DESIR and the SPACE cohorts [31, 32],
which reported that 40% and 50% of patients,
respectively, met the clinical arm criteria.
This study had several limitations; therefore,
the results should be interpreted with caution.
They are, however, mostly supportive of the
current literature and informative for any
healthcare professional dealing with early
diagnosis of SpA. Because of the
non-interventional nature of the study, it was
not mandatory for the orthopedist, PMR
physician or ophthalmologist to refer all
patients included in the study to a
rheumatologist. This might have led to a
selection bias in the estimation of axial SpA in
patients with chronic back pain. The fact that
Table 2 continued
Patients With
conﬁrmed
diagnosis
With conﬁrmed diagnosis and
meeting referral criteria
With conﬁrmed diagnosis but
not meeting referral criteria
N5 37 N5 22 N5 15
Sacroiliitis on imaging (X-ray,
MRI, or CT scan)
21 (56.8) 11 (50.0) 10 (66.7)
CRP C-reactive protein, ESR erythrocyte sedimentation rate, HLA human leukocyte antigen, IBP inﬂammatory back pain,
n number of patients in the speciﬁed category, NSAID nonsteroidal anti-inﬂammatory drug, SD standard deviation, SpA
axial spondyloarthritis
a HLA-B27 was not systematically requested by the investigator or rheumatologist but was only collected in the CRF when
results were available. Therefore the proportion of patients with positive HLA-B27 results is not presented (total number of
patients tested for HLA-B27 and number of patients with negative HLA-B27 results is unknown)
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not all patients referred to a rheumatologist
satisfied the referral criteria as stipulated in the
protocol (44%) introduces another bias that
may have complicated the interpretation of the
sensitivity and specificity of the referral criteria
used. This fact, combined with the limited
number of patients included in the study, led
to the decision to not compute the sensitivity
and specificity of the referral criteria. Another
limitation was that feedback from the
rheumatologist was only received from 85
patients out of the 117 patients who were
referred. It could be suggested that the
rheumatologists provided feedback more
readily in the case of a patient diagnosed with
SpA, which may have led to another bias in the
estimation of the prevalence of SpA.
CONCLUSIONS
The high percentage of axial SpA in patients
with chronic back pain visiting PMR physicians,
orthopedists, and ophthalmologists in this
study suggests that these healthcare
professionals may play a key role in
shortening the delay between the first
symptoms and the formal diagnosis of axial
SpA. The fact that approximately 40% of the
patients with a confirmed diagnosis did not
meet the referral criteria of the study (four of
five IBP criteria and one additional SpA feature)
suggests that these criteria may be too stringent.
When the ASAS classification criteria for axial
SpA were applied, 89% of the diagnosed
patients were classified as having axial SpA,
with approximately one-third of patients
diagnosed according to the clinical arm of the
ASAS criteria.
Early diagnosis of SpA in patients with
chronic back pain could be improved by
appropriate education and information on
axial SpA for non-rheumatologists. Overall, the
recent developments that allow earlier
diagnosis, namely, the detection of
inflammation signs with MRI, the set-up of
referral strategies (of which the SUSPECT study
is a part), as well as the development of new
drug therapies may make a positive difference
in the diagnosis and early management of
patients with axial SpA.
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